Most Read Articles
Stephen Padilla, 28 Nov 2018
A low-carbohydrate diet increases energy expenditure during weight loss maintenance, consistent with the carbohydrate-insulin model, a study has shown. This metabolic effect may contribute to the success of obesity treatment, particularly among those with high insulin secretion.
Natalia Reoutova, 5 days ago

A hospital-based observational cohort study finds an association between higher fasting blood glucose (FBG) levels and unfavourable outcomes, including death, among Chinese patients with diabetes mellitus (DM) following acute ischaemic stroke (AIS).

Elaine Soliven, 6 days ago
Adding liraglutide to metformin led to a significantly longer duration of glycaemic control in patients with type 2 diabetes (T2D) compared with an oral antidiabetic drug (OAD), according to the LIRA-PRIME* study presented at ADA 2020.

Add-on fish oil lowers lipid levels in rosuvastatin-treated patients

26 Dec 2017

Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.

The trial randomized 201 patients (mean age 58.1 years; 62.7 percent male) to receive rosuvastatin 20 mg/d plus ω-3 fatty acids 4 g/d (ROSUMEGA group) or rosuvastatin 20 mg/d (rosuvastatin group) alone for 8 weeks. All patients had residual hypertriglyceridemia following a 4-week run-in period of rosuvastatin treatment.

Compared with those in the rosuvastatin group, patients in the ROSUMEGA group showed a significantly greater percentage change from baseline in triglycerides (–26.3 vs –11.4 percent; p<0.001) and non-HDL cholesterol (–10.7 vs –2.2 percent; p=0.001) following 8 weeks of treatment.

Linear regression analysis found that the lipid-lowering effect of omega-3 fatty acids was more pronounced when baseline triglycerides or non-HDL cholesterol levels were high and body mass index was low.

In terms of safety, the incidence of adverse events did not significantly differ between the two treatment groups.

Researchers pointed out that additional work must be conducted to determine whether the lipid-lowering effect of omega-3 fatty acids actually leads to the prevention of cardiovascular event.

Omega-3 fatty acids are derived from fatty fish and other seafood, and their consumption has been previously reported to decrease plasma triglycerides, resting heart rate, and blood pressure, as well as also improve myocardial filling and efficiency, lower inflammation, and improve vascular function. Omega-3 fatty acids affect multiple molecular pathways, including alteration of physical and chemical properties of cellular membranes, direct interaction with and modulation of membrane channels and proteins, regulation of gene expression via nuclear receptors and transcription factors, changes in eicosanoid profiles, and conversion of n-3 PUFA to bioactive metabolites. [J Am Coll Cardiol 2011;58:2047–2067]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 28 Nov 2018
A low-carbohydrate diet increases energy expenditure during weight loss maintenance, consistent with the carbohydrate-insulin model, a study has shown. This metabolic effect may contribute to the success of obesity treatment, particularly among those with high insulin secretion.
Natalia Reoutova, 5 days ago

A hospital-based observational cohort study finds an association between higher fasting blood glucose (FBG) levels and unfavourable outcomes, including death, among Chinese patients with diabetes mellitus (DM) following acute ischaemic stroke (AIS).

Elaine Soliven, 6 days ago
Adding liraglutide to metformin led to a significantly longer duration of glycaemic control in patients with type 2 diabetes (T2D) compared with an oral antidiabetic drug (OAD), according to the LIRA-PRIME* study presented at ADA 2020.